Zylox-Tonbridge Medical Technology Future Growth
Future criteria checks 5/6
Zylox-Tonbridge Medical Technology is forecast to grow earnings and revenue by 66.5% and 34% per annum respectively. EPS is expected to grow by 66.9% per annum. Return on equity is forecast to be 6.7% in 3 years.
Key information
66.5%
Earnings growth rate
66.9%
EPS growth rate
| Medical Equipment earnings growth | 41.2% |
| Revenue growth rate | 34.0% |
| Future return on equity | 6.7% |
| Analyst coverage | Low |
| Last updated | 19 Dec 2024 |
Recent future growth updates
Recent updates
Market Participants Recognise Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) Revenues Pushing Shares 27% Higher
Oct 02
Solid Earnings Reflect Zylox-Tonbridge Medical Technology's (HKG:2190) Strength As A Business
Sep 27Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) Shares May Have Run Too Fast Too Soon
Apr 23Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Shares Could Be 48% Below Their Intrinsic Value Estimate
Jan 18Does This Valuation Of Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Imply Investors Are Overpaying?
Sep 21There's Reason For Concern Over Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) Price
Aug 03We're Not Very Worried About Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Rate
Jun 30Is Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Trading At A 45% Discount?
Mar 08We're Not Very Worried About Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Rate
Jan 19Here's Why We're Not Too Worried About Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Situation
Jul 06We're Hopeful That Zylox-Tonbridge Medical Technology (HKG:2190) Will Use Its Cash Wisely
Jan 27Here's Why We're Not At All Concerned With Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Situation
Oct 05Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,533 | 309 | N/A | 327 | 3 |
| 12/31/2025 | 1,120 | 198 | N/A | 211 | 3 |
| 12/31/2024 | 789 | 116 | N/A | 18 | 3 |
| 6/30/2024 | 664 | 26 | 23 | 221 | N/A |
| 3/31/2024 | 596 | -27 | -35 | 160 | N/A |
| 12/31/2023 | 528 | -79 | -92 | 98 | N/A |
| 9/30/2023 | 470 | -101 | -171 | 19 | N/A |
| 6/30/2023 | 411 | -124 | -250 | -60 | N/A |
| 3/31/2023 | 373 | -119 | -244 | -76 | N/A |
| 12/31/2022 | 334 | -114 | -237 | -91 | N/A |
| 9/30/2022 | 297 | -135 | -242 | -107 | N/A |
| 6/30/2022 | 259 | -155 | -247 | -122 | N/A |
| 3/31/2022 | 219 | -178 | -227 | -119 | N/A |
| 12/31/2021 | 178 | -200 | -206 | -116 | N/A |
| 9/30/2021 | 137 | -168 | -186 | -107 | N/A |
| 6/30/2021 | 97 | -135 | -166 | -98 | N/A |
| 3/31/2021 | 62 | -118 | -147 | -90 | N/A |
| 12/31/2020 | 28 | -100 | -127 | -82 | N/A |
| 12/31/2019 | 5 | -67 | -95 | -53 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2190's forecast earnings growth (66.5% per year) is above the savings rate (2.3%).
Earnings vs Market: 2190's earnings (66.5% per year) are forecast to grow faster than the Hong Kong market (11.6% per year).
High Growth Earnings: 2190's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 2190's revenue (34% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).
High Growth Revenue: 2190's revenue (34% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2190's Return on Equity is forecast to be low in 3 years time (6.7%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 10:59 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zylox-Tonbridge Medical Technology Co., Ltd. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shuo Song | Citic Securities Co., Ltd. |
| null null | Guoyuan Securities (HK) Ltd |
| Youjue Hu | Morgan Stanley |